This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nishi, M. Articles by Shoelson, S. E. Search for Related Content PubMed PubMed Citation Articles by Nishi, M. Articles by Shoelson, S. E.

Kinase Activation through Dimerization by Human SH2-B

Masahiro Nishi, Eric D. Werner, Byung-Chul Oh, J. Daniel Frantz, Sirano Dhe-Paganon, Lone Hansen, Jongsoon Lee, and Steven E. Shoelson^*

Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts

Received 17 November 2004/ Accepted 21 December 2004

The isoforms of SH2-B, APS, and Lnk form a family of signaling proteins that have been described as activators, mediators, or inhibitors of cytokine and growth factor signaling. We now show that the three alternatively spliced isoforms of human SH2-B readily homodimerize in yeast two-hybrid and cellular transfections assays, and this is mediated specifically by a unique domain in its amino terminus. Consistent with previous reports, we further show that the SH2 domains of SH2-B and APS bind JAK2 at Tyr813. These findings suggested a model in which two molecules of SH2-B or APS homodimerize with their SH2 domains bound to two JAK2 molecules, creating heterotetrameric JAK2-(SH2-B)₂-JAK2 or JAK2-(APS)₂-JAK2 complexes. We further show that APS and SH2-B isoforms heterodimerize. At lower levels of SH2-B or APS expression, dimerization approximates two JAK2 molecules to induce transactivation. At higher relative concentrations of SH2-B or APS, kinase activation is blocked. SH2-B or APS homodimerization and SH2-B/APS heterodimerization thus provide direct mechanisms for activating and inhibiting JAK2 and other kinases from the inside of the cell and for potentiating or attenuating cytokine and growth factor receptor signaling when ligands are present.

This study is dedicated to the memory of our friend and colleague, Valerie Fanikos.

M.N., E.D.W., and B.-C.O. contributed equally to this study.

This article has been cited by other articles:

• Li, Z., Zhou, Y., Carter-Su, C., Myers, M. G. Jr., Rui, L. (2007). SH2B1 Enhances Leptin Signaling by Both Janus Kinase 2 Tyr813 Phosphorylation-Dependent and -Independent Mechanisms. Mol. Endocrinol. 21: 2270-2281 [Abstract] [Full Text]  
• Yoshiga, D., Sato, N., Torisu, T., Mori, H., Yoshida, R., Nakamura, S., Takaesu, G., Kobayashi, T., Yoshimura, A. (2007). Adaptor Protein SH2-B Linking Receptor-Tyrosine Kinase and Akt Promotes Adipocyte Differentiation by Regulating Peroxisome Proliferator-Activated Receptor {gamma} Messenger Ribonucleic Acid Levels. Mol. Endocrinol. 21: 1120-1131 [Abstract] [Full Text]  
• Li, M., Li, Z., Morris, D. L., Rui, L. (2007). Identification of SH2B2{beta} as an Inhibitor for SH2B1- and SH2B2{alpha}-Promoted Janus Kinase-2 Activation and Insulin Signaling. Endocrinology 148: 1615-1621 [Abstract] [Full Text]  
• Kurzer, J. H., Saharinen, P., Silvennoinen, O., Carter-Su, C. (2006). Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State.. Mol. Cell. Biol. 26: 6381-6394 [Abstract] [Full Text]  
• Li, M., Ren, D., Iseki, M., Takaki, S., Rui, L. (2006). Differential Role of SH2-B and APS in Regulating Energy and Glucose Homeostasis. Endocrinology 147: 2163-2170 [Abstract] [Full Text]